Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-κB binding activity

Hormone and Metabolic Research

Volumn 39, Issue 9, 2007, Pages 665-671

  Rudofsky Jr , G ^a   Reismann, P ^a   Grafe, I A ^a   Konrade, I ^a   Djuric, Z ^a   Tafel, J ^a   Buchbinder, S ^a   Zorn, M ^a   Humpert, P M ^a   Hamann, A ^a   Morcos, M ^a   Nawroth, P P ^a   Bierhaus, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Endothelial function; Flow mediated vasodilatation; NF B activity; Pioglitazone; Type 2 diabetes

Indexed keywords

INTERLEUKIN 6; PIOGLITAZONE; PLACEBO; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NF KAPPAB; UNCLASSIFIED DRUG;

ADULT; AGED; BINDING AFFINITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

ADULT; AGED; AGED, 80 AND OVER; BRACHIAL ARTERY; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NF-KAPPA B; PLACEBOS; THIAZOLIDINEDIONES; VASODILATION;

ANIMALIA;

EID: 34848855823     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-985395     Document Type: Conference Paper

References (47)

1. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standi E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289
2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412
3. Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 2006; 29: 1039-1045
4. Suzuki M, Takamisawa I, Yoshimasa Y, Harano Y. Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. Diabetes Res Clin Pract 2007; 76: 12-17
5. Martens FM, Visseren FL, Koning EJ de, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 2005; 46: 773-778
6. Da Ros R, Assaloni R, Ceriello A. The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabet Med 2004; 21: 1249-1252
7. Fukunaga Y, Itoh H, Doi K, Tanaka T, Yamashita J, Chun TH, Inoue M, Masatsugu K, Sawada N, Saito T, Hosoda K, Kook H, Ueda M, Nakao K. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 2001; 158: 113-119
8. Taniguchi J, Honda H, Shibusawa Y, Iwata T, Notoya Y. Alteration in endothelial function and modulation by treatment with pioglitazone in rabbit renal artery from short-term hypercholesterolemia. Vascul Pharmacol 2005; 43: 47-55
9. Kutuk O, Basaga H. Inflammation meets oxidation: NF-kappaB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med 2003; 9: 549-557
10. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP. The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors 1999; 10: 157-167
11. Bierhaus A, Nawroth PP. Modulation of the vascular endothelium during infection-the role of NF-kappaB activation. Contrib Microbiol 2003; 10: 86-105
12. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NF-kappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002; 45: 147-154
13. Jung KJ, Kim JY, Zou Y, Kim YJ, Yu BP, Chung HY. Effect of short-term, low dose aspirin supplementation on the activation of pro-inflammatory NF-kappaB in aged rats. Mech Ageing Dev 2006; 127: 223-230
14. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265
15. Bots ML, Westerink J, Rabelink TJ, Koning EJ de. Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Heart 2005; 26: 363-368
16. Hofmann MA, Schiekofer S, Kanitz M, Klevesath MS, Joswig M, Lee V, Morcos M, Tritschler H, Ziegler R, Wahl P, Bierhaus A, Nawroth PP. Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 1998; 21: 1310-1316
17. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Hating HU, Schleicher E, Nawroth PP. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50: 2792-2808
18. Bierhaus A, Chevion S, Chevion M, Quehenberger P, Hofmann M, Illmer T, Luther T, Berentshtein E, Tritschler H, Müller M. Advanced glycation endproducts (AGEs) induced activation of NF-κB is suppressed by 2-lipoic acid in cultured endothelial cells. Diabetes 1997; 46: 1481-1490
19. Bierhaus A, Zhang Y, Deng Y, Mackman N, Quehenberger P, Haase M, Luther T, Müller M, Bohrer H, Greten J. Mechanism of the TNFα mediated induction of endothelial tissue factor. J Biol Chem 1995; 270: 26419-26432
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1996; 72: 248-254
21. Schiekofer S, Rudofsky G, Andrassy M, Schneider J, Chen J, Isermann B, Kanitz M, Elsenhans S, Heinle H, Balletshofer B, Haring HU, Schleicher E, Nawroth PP, Bierhaus A. Glimepiride reduces mononuclear activation of the redox-sensitive transcription factor nuclear factor-kappa B. Diabetes Obes Metab 2003; 5: 251-261
22. Rudofsky Jr G, Reismann P, Schiekofer S, Petrov D, Eynatten M, Humpert PM, Isermann B, Muller-Hoff C, Thai TP, Lichtenstein S, Bartsch U, Hamann A, Nawroth P, Bierhaus A. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm Metab Res 2004; 36: 630-638
23. Bierhaus A, Chevion S, Chevion M, Quehenberger P, Hofmann M, Illmer T, Luther T, Berentshtein E, Tritschler H, Müller M. Advanced glycation endproducts (AGEs) induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells. Diabetes 1997; 46: 1481-1490
24. Pahl HL, Baeuerle PA. Expression of influenza virus hemagglutinin activates the transcription factor NFκB. J Virol 1995; 69: 1480-1484
25. Eynatten M von, Schneider JG, Humpert PM, Rudofsky G, Schmidt N, Barosch P, Hamann A, Morcos M, Kreuzer J, Bierhaus A, Nawroth PP, Dugi KA. Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care 2004; 27: 2925-2929
26. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-1904
27. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, Fronzo RA De, Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105: 311-320
28. Madonna R, Pandolfi A, Massaro M, Consoli A, Caterina R De. Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase. Diabetologia 2004; 47: 532-536
29. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004; 94: 1168-1178
30. Stumvoll M, Goldstein BJ, Haeften TW van. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346
31. Haider DG, Leuchten N, Schaller G, Gouya G, Kolodjaschna J, Schmetterer L, Kapiotis S, Wolzt M. C-reactive protein is expressed and secreted by peripheral blood mononuclear cells. Clin Exp Immunol 2006; 146: 533-539
32. Park KG, Lee KM, Chang YC, Magae J, Ando K, Kim KB, Kim YN, Kim HS, Park JY, Lee KU, Lee IK. The ascochlorin derivative, AS-6, inhibits TNF-alpha-induced adhesion molecule and chemokine expression in rat vascular smooth muscle cells. Life Sci 2006; 80: 120-126
33. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001; 50: 3-11
34. Artwohl M, Holzenbein T, Fumsinn C, Freudenthaler A, Huttary N, Waldhausl WK, Baumgartner-Parzer SM. Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells. Thromb Haemost 2005; 93: 810-815
35. Srinivasan S, Hatley ME, Reilly KB, Danziger EC, Hedrick CC. Modulation of PPARalpha expression and inflammatory interleukin-6 production by chronic glucose increases monocyte/endothelial adhesion. Arterioscler Thromb Vasc Biol 2004; 24: 851-857
36. Marx N, Walcher D, Ivanova N, Rautzenberg K, Jung A, Friedl R, Hombach V, Caterina R de, Basta G, Wautier MP, Wautiers JL. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004; 53: 2662-2668
37. Edelstein LC, Pan A, Collins T. Chromatin modification and the endothelial-specific activation of the E-selectin gene. J Biol Chem 2005; 280: 11192-11202
38. Goldberg RB. Impact of thiazolidenediones on serum lipoprotein levels. Curr Atheroscler Rep 2006; 8: 397-404
39. Khan M, Murray FT, Karunaratne M, Perez A. Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 31-38
40. Al Majali K, Cooper MB, Staels B, Luc G, Taskinen MR, Betteridge DJ. The effect of sensitisation to insulin with pioglitazone on fasting and post-prandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 2006; 49:527-537
41. Mori Y, Ojima K, Fuujimori Y, Aoyagi I, Kusama H, Yamazaki Y, Kojima M, Shibata N, Itoh Y, Tajima N. Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats. Endocrine 2006; 29: 309-315
42. Gastaldelli A, Casolaro A, Pettiti M, Nannipieri M, Ciociaro D, Frascerra S, Buzzigoli E, Baldi S, Mari A, Ferrannini E. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes. Clin Pharmacol Ther 2007; 81: 205-212
43. Suzuki M, Takamisawa I, Yoshimasa Y, Harano Y. Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. Diabetes Res Clin Pract 2007; 76: 12-17
44. Title LM, Cummings PM, Giddens K, Nassar BA. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. J Am Coll Cardiol 2000; 36: 2185-2191
45. Westphal S, Taneva E, Kastner S, Martens-Lobenhoffer J, Bode-Boger S, Kropf S, Dierkes J, Luley C. Endothelial dysfunction induced by post-prandial lipemia is neutralized by addition of proteins to the fatty meal. Atherosclerosis 2006; 185: 313-319
46. Tushuizen ME, Nieuwland R, Scheffer PG, Sturk A, Heine RJ, Diamant M. Two consecutive high-fat meals affect endothelial-dependent vasodilation, oxidative stress and cellular microparticles in healthy men. J Thromb Haemost 2006; 4: 1003-1010
47. Chappuis B, Braun M, Stettler C, Allemann S, Diem P, Lumb PJ, Wierzbicki AS, James R, Christ ER. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev 2007; 23: 392-399